Xtandi
May 29, 2026
Cracks in the mCRPC Treatment Market: 8 Companies at Risk of Falling Behind
Summary The mCRPC market, valued at around USD 8 billion in 2025, is undergoing rapid disruption driven by scientific innovation, patent expirations, and shifting treatment paradigms. Once dominated by blockbuster androgen receptor inhibitors like ZYTIGA and XTANDI, the landscape is now fragmenting under pre...
Read More...
Dec 01, 2023
Could Amgen’s Biosimilar Wezlana Pose a Challenge to Johnson & Johnson’s Stelara
The FDA recently approved Amgen’s Wezlana (ustekinumab-auub) for various inflammatory conditions, marking the first biosimilar approval referencing the popular J&J drug Stelara (ustekinumab). Wezlana, mirroring its reference product, is approved for treating multiple inflammatory diseases in adults, including m...
Read More...
Nov 27, 2023
Another Feather in the Cap for Xtandi and Keytruda — The Two Main Cancer Drugs
The FDA has approved label extensions for two of the most crucial cancer medications globally—Merck’s Keytruda and Pfizer and Astellas’ Xtandi. Keytruda’s expanded indication now includes stomach cancer, permitting its usage alongside chemotherapy for first-line treatment in patients with locally advanced unresecta...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
